Market Insights

Daiichi Sankyo has launched the Phase I trial of CD25 ADC DS1025a (WO2024204629), recruiting 45 advanced solid tumor patients with interim data due Jan 2028. Built on the mature DXd ADC platform, the agent revitalizes CD25 immunotherapy research. This paper elaborates CD25 biological functions, DS1025a’s mode of action and nanobodies’ superior strengths over traditional full-length mAbs for CD25 drug discovery.

A landmark study recently published in Signal Transduction and Targeted Therapy fully validates the irreplaceable value of nanobodies in cutting-edge innovative immunotherapies. Leveraging nanobody technology, the research team developed the world’s first TCR-mimetic bispecific nanobody-based T-cell engager (TCRm Bi-NbTE). This pioneering platform enables precise targeted therapy against intracellular tumor antigens, filling critical technical gaps left by conventional antibody therapeutics.

On June 12, 2026, XKH001, an anti-IL-25 monoclonal antibody injection, completed the first patient dosing in its Phase II clinical trial for COPD. This milestone signifies a key breakthrough of the IL-25 target in respiratory disease therapy, and also leads the industry to look into the development potential of nanobodies, the cutting-edge next-generation antibody technology.

Published online May 12, 2026, in BMC Biotechnology, an international team led by the Pasteur Institute of Iran has developed two humanized anti-VEGF nanobody variants—MHNb136 and MHNb256—with affinity superior to bevacizumab, providing promising next-generation anti-angiogenic candidates for ocular diseases and cancer.

Recently, a major breakthrough has been announced in the biopharmaceutical industry: SIM0613, an innovative LRRC15-targeted antibody-drug conjugate (ADC) developed by Simcere Zaiming, has been officially approved for clinical trials. With outstanding preclinical data, this drug has secured an ...

BackgroundTreatment of advanced solid tumors remains highly challenging. Conventional chemotherapy and targeted therapies suffer from poor specificity, frequent drug resistance, and severe side effects. Most patients lose the chance for curative surgery and face poor prognosis. Combining preci...

Cystic fibrosis (CF) is a common life-threatening autosomal recessive disorder affecting millions worldwide. The F508del-CFTR (cystic fibrosis transmembrane conductance regulator) mutation is the primary pathogenic culprit, present in approximately 90% of CF patients. For decades, repairing the p...

Zai Lab and Boehringer Ingelheim have partnered to develop DLL3-targeted dual therapies for ES-SCLC and NEC. The collaboration combines Obrixtamig and Zai Lab’s DLL3 ADC, spotlighting DLL3 as a key target and nanobody technology’s transformative role in antibody drug development.

Recently, nanobody applications in oncology have achieved a major breakthrough: JSKN016, a bispecific ADC independently developed by Alphamab Oncology, has dosed its first patient in a Phase III trial. This milestone signifies that nanobody‑enabled innovative drug R&D has entered a critical phase, highlighting the clinical value and application potential of nanobodies.

A Chinese team’s latest study in Nature Communications developed BA2-1A10, the world’s first potent broad‑spectrum bispecific anti‑Ebola agent based on camel nanobodies. It overcomes the single‑strain limitation of conventional antibodies, shows excellent efficacy in vitro and in vivo, and highlights the great potential of nanobodies.

Solid tumor innovative therapy advances: US FDA approves IND for injectable HDM2024, an EGFR/HER3 dual-target Bs-ADC. A Phase I trial for advanced solid tumors will launch in the US. The drug’s unique dual-target synergy brings a new option for drug-resistant solid tumors, and this article analyzes its core mechanism and clinical value via target interpretation.

In March 2026, the Chinese innovative drug sector received exciting news — MWX401 Injection, an independently developed small interfering